In the wake of the COVID-19 pandemic, the landscape of cell and gene therapy (CGT) manufacturing has witnessed significant transformation. The industry has seen an increased emphasis on the advantages of advanced therapy medicinal products (ATMPs) and the push for increases in manufacturing scale and overall availability to larger populations. ATMPs find themselves at a critical juncture where...